To evaluate the efficacy and safety of using genetic information to guide warfarin dosing in the Chinese population.
This meta-analysis was conducted among the published, randomized, controlled trials (RCTs) in the Chinese population comparing genotype-guided warfarin dosing (PG group) with clinical or standard warfarin dosing (STD group). RCTs published on or before January 2018 were identified using the PubMed, Embase, Cochrane Library, CNKI, Chinese VIP database, and Chinese Wanfang database.
Intotal, 2137 participants from 14 RCTs were included in the meta-analysis. Primary analysis showed that both bleeding events [odds ratio (OR) = 0.24; 95% confidence interval (CI), 0.11–0.52; P = 0.0003] and adverse events (OR = 0.60; 95% CI, 0.43–0.83; P = 0.002) were significantly lower in the genotype-guided group than in the clinical or standard group. The percentage of patients who received a warfarin-stable therapeutic dose during follow-up was increased in the genotype-guided group compared with the percentage in the clinical or standard group (OR = 2.68; 95% CI, 1.82–3.95; P < 0.00001). In the genotype-guided group, the time to a stable therapeutic dose (mean difference = −7.98; 95% CI, −9.08 to −6.87; P < 0.00001) and the time to the first target value (mean difference = −1.87; 95% CI, −3.41 to −0.32; P = 0.02) were shortened compared with those of the clinical or standard group, but there was no difference for international normalized ratio >4, between the 2 groups (OR = 0.42; 95% CI, 0.14–1.25; P = 0.12).
Genotype-guided warfarin-dosing algorithms could improve the efficacy and safety of warfarin anticoagulation in the Chinese population.